The need for activation before effective GITR ligation is also consistent with our prior study combining DTA-1 with xenogeneic DNA vaccination, in which DTA-1 augmented CD8+ responses and tumor protection only when administered with the second vaccination, and was ineffective when given prior to the initial priming vaccine.[16]. The gene discussed is TNFRSF18; the disease is neoplasm.